Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 7 November 1997:
Vol. 278. no. 5340, pp. 1041 - 1042
DOI: 10.1126/science.278.5340.1041
Prev | Table of Contents | Next

News

CANCER MODELS:
Systems for Identifying New Drugs Are Often Faulty

Trisha Gura

Screening potential anticancer agents to find ones promising enough to make human clinical trials worthwhile has not been as straightforward as researchers would like. Not only have very few of the drugs that showed anticancer activity in animals carrying transplanted human tumors--known as xenografts--made it into the clinic, but a recent study conducted at the National Cancer Institute suggests that the tests are also missing drugs that do work in humans, possibly because animals and humans do not handle the drugs exactly the same way. And attempts to use human cells in culture don't seem to be faring any better, partly because cell culture provides no information about whether a drug will make it to the tumor site. To create better models of cancer development in humans, investigators are now drawing on knowledge of human cancer-related gene mutations to genetically alter mice so that they carry the same kinds of changes that lead to cancer in humans. The hope is that the mice will develop tumors that behave the same way the human tumors do.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Contributions of human tumor xenografts to anticancer drug development..
E. A. Sausville, A. M. Burger, O. J. Becher, and E. C. Holland (2006)
Cancer Res. 66, 3351-3354
   Abstract »    Full Text »    PDF »
Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice..
F E Utama, M J LeBaron, L M Neilson, A S Sultan, A F Parlow, K-U Wagner, and H Rui (2006)
J. Endocrinol. 188, 589-601
   Abstract »    Full Text »    PDF »
Inhibitory Effect of Antagonists of Bombesin and Growth Hormone-Releasing Hormone on Orthotopic and Intraosseous Growth and Invasiveness of PC-3 Human Prostate Cancer in Nude Mice.
A. Stangelberger, A. V. Schally, J. L. Varga, M. Zarandi, K. Szepeshazi, P. Armatis, and G. Halmos (2005)
Clin. Cancer Res. 11, 49-57
   Abstract »    Full Text »    PDF »
A New Mouse Model for Evaluating the Immunotherapy of Human Colorectal Cancer.
H. Horig, A. Wainstein, L. Long, D. Kahn, S. Soni, A. Marcus, W. Edelmann, R. Kucherlapati, and H. L. Kaufman (2001)
Cancer Res. 61, 8520-8526
   Abstract »    Full Text »    PDF »
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors.
R. W. Wilkinson, E. L. Ross, R. Poulsom, M. Ilyas, J. Straub, D. Snary, W. F. Bodmer, and S. J. Mather (2001)
PNAS
   Abstract »    Full Text »    PDF »
Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?.
K. A. Gelmon, E. A. Eisenhauer, A. L. Harris, M. J. Ratain, and P. Workman (1999)
J Natl Cancer Inst 91, 1281-1287
   Full Text »    PDF »
Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents.
J. M. Brown and B. G. Wouters (1999)
Cancer Res. 59, 1391-1399
   Abstract »    Full Text »    PDF »
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors.
R. W. Wilkinson, E. L. Ross, R. Poulsom, M. Ilyas, J. Straub, D. Snary, W. F. Bodmer, and S. J. Mather (2001)
PNAS 98, 10256-10260
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)